Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab Versus Short-course Radiotherapy Plus Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer

NCT07674732 is registered in ClinicalTrials.gov with Dechang Diao as lead sponsor.

NCT NCT07674732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab Versus Short-course Radiotherapy Plus Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer
Lead sponsor
Dechang Diao
Phase
Phase 2
Overall status
Recruiting
Start date
June 24, 2026
Completion date
June 24, 2029
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nodal-region sparing short-course radiotherapy followed by sequential chemotherapy with pd-1 monoclonal antibody and bevacizumab, short-course radiotherapy plus chemotherapy